Case Histories
Articles in this series discuss the discovery and development of particular drugs or drug classes. Written by those closely involved in the discovery process, these aim to provide insights that will aid in future drug discovery programs.
2012
November 2012 Vol 11 No 11
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag, James Tsai, Jiazhong Zhang, Chao Zhang, Prabha Ibrahim, Keith Nolop & Peter Hirth
doi:10.1038/nrd3847
May 2012 Vol 11 No 5
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
David L. Lacey, William J. Boyle, W. Scott Simonet, Paul J. Kostenuik, William C. Dougall, John K. Sullivan, Javier San Martin & Roger Dansey
doi:10.1038/nrd3705
2011
January 2011 Vol 10 No 1
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza & Frank Misselwitz
doi:10.1038/nrd3185
2010
November 2010 Vol 9 No 11
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Volker Brinkmann, Andreas Billich, Thomas Baumruker, Peter Heining, Robert Schmouder, Gordon Francis, Shreeram Aradhye & Pascale Burtin
p883 | doi:10.1038/nrd3248
August 2010 Vol 9 No 8
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
Christian de Bodinat, Béatrice Guardiola-Lemaitre, Elisabeth Mocaër, Pierre Renard, Carmen Muñoz & Mark J. Millan
p628 | doi:10.1038/nrd3140
2008
May 2008 Vol 7 No 5
Aliskiren: the first renin inhibitor for clinical treatment
Chris Jensen, Peter Herold & Hans Rudolf Brunner
p399 | doi:10.1038/nrd2550
2007
December 2007 Vol 6 No 12
The war against influenza: discovery and development of sialidase inhibitors
Mark von Itzstein
p967 | doi:10.1038/nrd2400
September 2007 Vol 6 No 9
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre, George Demetri, William Sargent & Eric Raymond
p734 | doi:10.1038/nrd2380
2006
February 2006 Vol 5 No 2
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Eugene W. M. Ng, David T. Shima, Perry Calias, Emmett T. Cunningham, Jr., David R. Guyer and Anthony P. Adamis
p123 | doi:10.1038/nrd1955
2005
September 2005 Vol 4 No 9
The discovery of fluoxetine hydrochloride (Prozac)
David T. Wong, Kenneth W. Perry & Frank P. Bymaster
p764 | doi:10.1038/nrd1821
2004
August 2004 Vol 3 No 8
A new oral anticoagulant: the 50-year challenge
David Gustafsson, Ruth Bylund, Thomas Antonsson, Ingemar Nilsson, Jan-Erik Nystr�m, Ulf Eriksson, Ulf Bredberg & Ann-Catrine Teger-Nilsson
p649 | doi:10.1038/nrd1466
May 2004 Vol 3 No 5
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Napoleone Ferrara, Kenneth J. Hillan, Hans-Peter Gerber & William Novotny
p391 | doi:10.1038/nrd1381
March 2004 Vol 3 No 3
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Tom Matthews, Miklos Salgo, Michael Greenberg, Jain Chung, Ralph DeMasi & Dani Bolognesi
p215 | doi:10.1038/nrd1331
2003
July 2003 Vol 2 No 7
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Jonathan A. Tobert
p517 | doi:10.1038/nrd1112
March 2003 Vol 2 No 3
The development of COX2 inhibitors
Rod J. Flower
p179 | doi:10.1038/nrd1034
Tamoxifen: a most unlikely pioneering medicine
V. Craig Jordan
p205 | doi:10.1038/nrd1031
February 2003 Vol 2 No 2
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole
Lars Olbe, Enar Carlsson & Per Lindberg
p132 | doi:10.1038/nrd1010
2002
July 2002 Vol 1 No 7
Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug
Renaud Capdeville, Elisabeth Buchdunger, Juerg Zimmermann & Alex Matter
p493 | doi:10.1038/nrd839
© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.
